InVivo Therapeutics to Present at Needham and Company’s 16th Annual Healthcare Conference

CAMBRIDGE, Mass.--()--InVivo Therapeutics Holdings Corp. (NVIV) today announced that Mark Perrin, Chief Executive Officer and Chairman, will present at the Needham and Company’s 16th Annual Healthcare Conference on Wednesday, April 5, 2017 at 1:40 PM Eastern Time at the Westin NY Grand Central Hotel in New York, NY. This is the first time that the company has been invited to present at the Needham and Company Annual Healthcare Conference. During his presentation, Mr. Perrin will highlight the recent progress of the company’s Neuro-Spinal Scaffold™ program, and provide an overview of the company.

A live webcast will be available at http://wsw.com/webcast/needham80/nviv and a webcast replay will be available at the same address approximately one hour after the live webcast presentation. Please log in 5-10 minutes before the event to ensure a timely connection.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital and who now is affiliated with Massachusetts General Hospital. In 2011, the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. In 2015, the company’s investigational Neuro-Spinal Scaffold received the 2015 Becker’s Healthcare Spine Device Award. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.

Contacts

InVivo Therapeutics Holdings Corp.
Heather Hamel, 617-863-5530
Investor Relations
Investor-relations@invivotherapeutics.com

Contacts

InVivo Therapeutics Holdings Corp.
Heather Hamel, 617-863-5530
Investor Relations
Investor-relations@invivotherapeutics.com